As leaders of eight of Canada’s provincial health and life sciences organizations, we are writing to express concerns about the PMPRB’s impending decision on the above-noted proposed Guidelines changes. We strongly believe you should postpone any decisions related to this initiative for several important reasons.
Read MoreThe recent release of the Patented Medicine Prices Review Board’s modernized regulatory framework will negatively impact Canada’s competitiveness in attracting investment to commercialize Canadian innovation.
Read More